LLY News and Press, Eli Lilly and Company From 02/08/24

2024-02-08 11:57:41 ET Summary Eli Lilly and Company stock has seen a 21.8% increase since the article was written, outperforming the S&P 500. The company's strong earnings growth and potential for blockbuster drugs contribute to its continued success. The 5-year target pr...

2024-02-08 07:41:07 ET More on Foghorn Therapeutics Seeking Alpha’s Quant Rating on Foghorn Therapeutics Historical earnings data for Foghorn Therapeutics Financial information for Foghorn Therapeutics Read the full article on Seeking Alpha For...

2024-02-08 05:50:00 ET Eli Lilly (NYSE: LLY) had a very good year in 2023. Revenue jumped 20% and its stock skyrocketed 59%. The company also claimed the mantle as the world's largest drugmaker by market cap. Will the momentum continue going forward? Probably. However, it won't ...

2024-02-08 02:25:34 ET Summary Eli Lilly's tirzepatide shows potential in treating MASH, challenging Madrigal Pharmaceuticals' resmetirom. Despite Madrigal's solid financials, Eli Lilly's advancements hint at market recalibration, adversely affecting Madrigal's valuation and futur...

2024-02-07 18:00:06 ET Summary Eli Lilly and Company has seen significant growth and generated strong returns, outperforming the S&P 500. The company's revenue increased by 28.1% in the final quarter of 2023, exceeding analysts' expectations. While some drugs, like Trulici...

2024-02-07 17:43:49 ET More on Catalent Catalent - Novo Holdings Merger: Attractive Spread Catalent: Debt Remains An Overhang Catalent, Inc. (CTLT) Q1 2024 Earnings Call Transcript Catalent ticks lower amid report Indiana plant may have quality issues ...

2024-02-07 16:29:17 ET Summary We anticipate an FTC review for the Novo Holdings acquisition of Catalent, Inc. but see no grounds for blocking. Timetable risk due to regulatory approval under HSR Act. Attractive 10.2% gross spread with favourable probability of closing. ...

2024-02-07 09:34:00 ET More on Amgen Amgen Inc. (AMGN) Q4 2023 Earnings Call Transcript Amgen: Debt-Funded Buybacks Constrains Future Gains Per Share Amgen: Accelerating The Business And Dividend Growth Amgen Non-GAAP EPS of $4.71 beats by $0.12, revenue of $...

2024-02-07 02:30:31 ET Summary Fisher's 13F portfolio value increased by approximately 15% to $203 billion in Q4 2023. The number of holdings decreased from 1168 to 1161, with significantly large positions decreasing from 66 to 65. The top five individual stock positions in th...

2024-02-06 19:32:41 ET Summary Madrigal Pharmaceuticals is leading the race to secure approval for its drug Resmetirom to treat NASH, now known as MASH, a form of fatty liver disease. Eli Lilly's drug tirzepatide, which has already secured approvals for Type 2 diabetes and obesity...